Key result
Recombinant urokinase increases total patency restoration in occluded central venous catheters by ~80% versus placebo.
Why the study?
Does recombinant urokinase improve the restoration of total catheter patency in patients with occluded central venous access devices?
Population
180 adult and pediatric patients with occluded, non-hemodialysis central venous access devices of any…
Comparison
Recombinant urokinase 5000 IU/ml instilled into… vs Placebo instilled into all occluded lumens
Design
RCT, 2:1, double-blinded
Follow-up
72 hours
Authors
Loading...
May avoid catheter replacement for occluded central venous devices; confirms recombinant urokinase efficacy versus placebo in an RCT.
RCT (n=180)
Double-blinded
2:1
Yes
Does recombinant urokinase improve the restoration of total catheter patency in patients with occluded central venous access devices?
Absolute Event Rate: 54% vs 30%
p-value: p=0.002
Recombinant urokinase is superior to placebo in restoring patency to occluded central venous access devices, potentially obviating the need for catheter replacement.
Deitcher et al. (2004) conducted an RCT in Occluded central venous access devices (CVADs) (n=180). Recombinant urokinase (r-UK) vs. Placebo was evaluated on Restoration of catheter function to all treated lumens (total catheter patency) after one or two instillations (p=0.002). Instillation of recombinant urokinase was significantly better than placebo in restoring total catheter patency to occluded central venous access devices (54% vs 30%, p = 0.002).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: